Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 2Phase 4 1Phase 3 1

Status

Completed 17Terminated 9Active not recruiting 6Recruiting 5Unknown 4Withdrawn 3Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Multiple Myeloma 1Lymphoma, Primary Effusion 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × pomalidomide × Clear all
NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

NCT05408026 2023-01-27

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Alliance Foundation Trials, LLC.

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡